We are live on ! Find out more
CRDF icon

Cardiff Oncology
CRDF

38 hedge funds and large institutions have $797K invested in Cardiff Oncology in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 8 increasing their positions, 13 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.13% less ownership

Funds ownership: 0.2% → 0.07% (-0.13%)

19% less funds holding

Funds holding: 47 → 38 (-9)

38% less repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 13

79% less capital invested

Capital invested by funds: $3.84M → $797K (-$3.04M)

89% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 9

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $1K

Holders
38
Holders Change
-9
Holders Change %
-19.15%
% of All Funds
0.86%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
8
Reduced
13
Closed
9
Calls
–
Puts
$1K
Net Calls
-$1K
Net Calls Change
-$2K

Top Buyers

1
TSS
Two Sigma Securities
New York
+$35.3K
2
CGA
Crescent Grove Advisors
Illinois
+$9.83K
3
MAM
Meeder Asset Management
Ohio
+$1.73K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$1.28K
5
Northern Trust
Northern Trust
Illinois
+$1.02K

Top Sellers

1
SM
Sabby Management
Florida
-$1.23M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$357K
3
Millennium Management
Millennium Management
New York
-$142K
4
DADC
D.A. Davidson & Co
Montana
-$116K
5
Vanguard Group
Vanguard Group
Pennsylvania
-$46K
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$238K -$46K -1,039 -9%
BlackRock
2
BlackRock
New York
$125K +$443 +10 +0.2%
EP
3
Elkhorn Partners
Nebraska
$89K – – –
PFS
4
Prospera Financial Services
Texas
$46K +$620 +14 +0.8%
Geode Capital Management
5
Geode Capital Management
Massachusetts
$42K -$6.47K -146 -7%
Millennium Management
6
Millennium Management
New York
$34K -$142K -3,208 -67%
CGA
7
Crescent Grove Advisors
Illinois
$26K +$9.83K +222 +23%
TSS
8
Two Sigma Securities
New York
$25K +$35.3K +798 +238%
California Public Employees Retirement System
9
California Public Employees Retirement System
California
$24K – – –
VF
10
Virtu Financial
New York
$22K -$4.52K -102 -9%
CAPTRUST Financial Advisors
11
CAPTRUST Financial Advisors
North Carolina
$19K – – –
Northern Trust
12
Northern Trust
Illinois
$18K +$1.02K +23 +3%
Bank of New York Mellon
13
Bank of New York Mellon
New York
$17K +$1.28K +29 +4%
Barclays
14
Barclays
United Kingdom
$8K – – –
MSTVIM
15
Messner & Smith Theme Value Investment Management
California
$7K -$1.9K -43 -11%
Cambridge Investment Research Advisors
16
Cambridge Investment Research Advisors
Iowa
$7K -$576 -13 -4%
Bank of Montreal
17
Bank of Montreal
Ontario, Canada
$7K – – –
RJA
18
Raymond James & Associates
Florida
$7K – – –
IAA
19
Independent Advisor Alliance
North Carolina
$6K – – –
Goldman Sachs
20
Goldman Sachs
New York
$5K +$266 +6 +3%
PCM
21
Princeton Capital Management
New Jersey
$5K +$10.5K +237 New
UBS Group
22
UBS Group
Switzerland
$4K -$11.6K -261 -58%
State Street
23
State Street
Massachusetts
$4K – – –
Morgan Stanley
24
Morgan Stanley
New York
$2K -$2.7K -61 -42%
Bank of America
25
Bank of America
North Carolina
$2K -$620 -14 -15%
1
2

CRDF Hedge Fund Activity: Q4 2017 in Review

38 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Cardiff Oncology (CRDF) for Q4 2017, worth a combined $797K — down 79% from $3.84M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of CRDF and 1 opened new positions — a net loss of 8 holders — while 13 trimmed existing stakes and 8 added.

The largest buyer was Two Sigma Securities, adding an estimated $35.3K. The largest seller was Sabby Management, exiting entirely with an estimated $1.23M sold.

  • 38 institutional investors held Cardiff Oncology (CRDF) as of Q4 2017, down from 47 in Q3 2017.
  • Funds reported $797K of Cardiff Oncology stock for Q4 2017, down 79% quarter-over-quarter.
  • 1 fund opened new Cardiff Oncology positions in Q4 2017 and 9 closed out, a net change of -8 holders.
  • The largest Cardiff Oncology buyer in Q4 2017 was Two Sigma Securities, an estimated $35.3K added.
  • The largest Cardiff Oncology seller in Q4 2017 was Sabby Management, an estimated $1.23M sold.

Based on aggregated 13F filings for Q4 2017.